WO2002096365A3 - Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy - Google Patents

Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy Download PDF

Info

Publication number
WO2002096365A3
WO2002096365A3 PCT/US2002/017069 US0217069W WO02096365A3 WO 2002096365 A3 WO2002096365 A3 WO 2002096365A3 US 0217069 W US0217069 W US 0217069W WO 02096365 A3 WO02096365 A3 WO 02096365A3
Authority
WO
WIPO (PCT)
Prior art keywords
photodynamic therapy
intravascular
efficacy
improving treatment
treatment selectivity
Prior art date
Application number
PCT/US2002/017069
Other languages
French (fr)
Other versions
WO2002096365A9 (en
WO2002096365A2 (en
Inventor
Steven J Rychnovsky
Original Assignee
Miravant Syst Inc
Steven J Rychnovsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miravant Syst Inc, Steven J Rychnovsky filed Critical Miravant Syst Inc
Priority to AU2002314846A priority Critical patent/AU2002314846B2/en
Publication of WO2002096365A2 publication Critical patent/WO2002096365A2/en
Publication of WO2002096365A9 publication Critical patent/WO2002096365A9/en
Publication of WO2002096365A3 publication Critical patent/WO2002096365A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Abstract

A method in which photodynamic therapy is employed to inhibit, stabilize or reduce occlusions within the cardiovascular system by utilizing light within the spectral region of approximately 390 to approximately 610 nm.
PCT/US2002/017069 2001-05-31 2002-05-31 Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy WO2002096365A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002314846A AU2002314846B2 (en) 2001-05-31 2002-05-31 Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/871,441 2001-05-31
US09/871,441 US6887862B2 (en) 2001-05-31 2001-05-31 Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy

Publications (3)

Publication Number Publication Date
WO2002096365A2 WO2002096365A2 (en) 2002-12-05
WO2002096365A9 WO2002096365A9 (en) 2003-01-09
WO2002096365A3 true WO2002096365A3 (en) 2003-05-01

Family

ID=25357438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/017069 WO2002096365A2 (en) 2001-05-31 2002-05-31 Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy

Country Status (3)

Country Link
US (2) US6887862B2 (en)
AU (1) AU2002314846B2 (en)
WO (1) WO2002096365A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US6887862B2 (en) * 2001-05-31 2005-05-03 Miravant Systems, Inc. Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy
US7223282B1 (en) * 2001-09-27 2007-05-29 Advanced Cardiovascular Systems, Inc. Remote activation of an implantable device
US20050049228A1 (en) * 2003-09-02 2005-03-03 Ceramoptec Industries Inc. Antimicrobial photodynamic therapy compound and method of use
US7553326B2 (en) * 2003-11-24 2009-06-30 Sweet Richard M Method and apparatus for preventing dialysis graft intimal hyperplasia
EP1853189A4 (en) * 2005-02-17 2011-06-29 Light Sciences Oncology Inc Photoreactive system and methods for prophylactic treatment of atherosclerosis
GB2442915B (en) 2005-08-10 2009-12-16 Quest Pharmatech Inc Perylenequinone derivatives and uses thereof
US20090326435A1 (en) * 2006-05-02 2009-12-31 Green Medical, Inc. Systems and methods for treating superficial venous malformations like varicose or spider veins
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
WO2007130465A2 (en) * 2006-05-02 2007-11-15 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US8454991B2 (en) * 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
EP2109689A4 (en) * 2007-02-07 2010-02-10 Perscitus Biosciences Llc Detection of molecule proximity
US9488916B2 (en) 2007-04-08 2016-11-08 Immunolight, Llc. Interior energy-activation of photo-reactive species inside a medium or body
USRE49724E1 (en) * 2008-09-29 2023-11-14 Tom Kerber Device for photodynamical therapy of cancer
US10195459B2 (en) * 2008-09-29 2019-02-05 Tom Kerber Device for photodynamical therapy of cancer
US11806549B2 (en) * 2017-12-05 2023-11-07 Lumen Catheters, LLC Method, system, and devices of safe, antimicrobial light-emitting catheters, tubes, and instruments

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054449A (en) * 1995-07-27 2000-04-25 Miravant Pharmaceuticals, Inc. Compounds and method for PDT of intimal hyperplasia and other diseases
WO2001024825A2 (en) * 1999-10-01 2001-04-12 The General Hospital Corporation Doing Business As Massachusetts General Hospital Significance of dosimetry in photodynamic therapy of injured arteries
WO2001035997A2 (en) * 1999-11-17 2001-05-25 Qlt Inc. Use of low-dose pdt to inhibit restenosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116864A (en) 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
JP3154742B2 (en) 1991-04-30 2001-04-09 日本石油化学株式会社 Remedy for mammalian atherosclerosis
US5354774A (en) 1992-12-24 1994-10-11 Yale University Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
WO1996029943A1 (en) 1995-03-28 1996-10-03 Eli Lilly And Company Photodynamic therapy system and method
US5620438A (en) 1995-04-20 1997-04-15 Angiomedics Ii Incorporated Method and apparatus for treating vascular tissue following angioplasty to minimize restenosis
US5964751A (en) 1996-08-26 1999-10-12 Illumenex Corporation Light delivery system with blood flushing capability
US5833682A (en) 1996-08-26 1998-11-10 Illumenex Corporation Light delivery system with blood flushing capability
US6071944A (en) 1997-11-12 2000-06-06 Bowling Green State University Method of treatment of pigmented cancer cells utilizing photodynamic therapy
US6221055B1 (en) * 1998-03-04 2001-04-24 Retractable Technologies, Inc. Retractable dental syringe
US6887862B2 (en) * 2001-05-31 2005-05-03 Miravant Systems, Inc. Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054449A (en) * 1995-07-27 2000-04-25 Miravant Pharmaceuticals, Inc. Compounds and method for PDT of intimal hyperplasia and other diseases
WO2001024825A2 (en) * 1999-10-01 2001-04-12 The General Hospital Corporation Doing Business As Massachusetts General Hospital Significance of dosimetry in photodynamic therapy of injured arteries
WO2001035997A2 (en) * 1999-11-17 2001-05-25 Qlt Inc. Use of low-dose pdt to inhibit restenosis

Also Published As

Publication number Publication date
WO2002096365A9 (en) 2003-01-09
AU2002314846B2 (en) 2006-02-23
WO2002096365A2 (en) 2002-12-05
US20020183301A1 (en) 2002-12-05
US20050130950A1 (en) 2005-06-16
US6887862B2 (en) 2005-05-03

Similar Documents

Publication Publication Date Title
WO2002096365A3 (en) Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
WO2003020202A3 (en) Method for reducing hypertension and heart failure
WO2000038717A3 (en) Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia
WO2003053336A3 (en) Methods for the treatment of peripheral neural and vascular ailments
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU2002321105A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
AU2001249881A1 (en) Method of treating the heart
WO2004000230A3 (en) Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
WO2003086460A3 (en) High fluence rate activation of photosensitizers for dermatological applications
WO2001060347A3 (en) Method for treating ocular pain
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
EP1716856A3 (en) The treatment of acne
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
WO2002028810A3 (en) Retinoids for the treatment of emphysema
WO2002094196A3 (en) Method of treatment for cancers associated with elevated
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
EP1120119A4 (en) Remedies for photochemotherapy
WO2003041644A3 (en) Method to treat cystic fibrosis
WO2005016270A3 (en) Methods for treatment of dermatological conditions
WO2003028629A3 (en) Chlorin photosensitizing agents for use in photodynamic therapy
WO2003028628A3 (en) Photosensitizing carbamate derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/15-15/15, DRAWINGS, REPLACED BY NEW PAGES 1/15-15/15; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002314846

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP